{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:56:14Z","timestamp":1792691774132,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejmech.2026.118743","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:00:56Z","timestamp":1772816456000},"page":"118743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["InhibitWin duo: Rational design and structural insights into dual PARP\/HDAC inhibitors for synergistic DNA repair disruption and epigenetic modulation"],"prefix":"10.1016","volume":"309","author":[{"given":"Eman M.","family":"Elkafoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"F El-Moselhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"H. El-Hamamsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"A El-Bastawissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Afarinkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.M.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf K.","family":"El-Damasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elshewy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Shawky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabah N.","family":"Alsulami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman R.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Jaragh-Alhadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/biomedicines12010183","article-title":"Overcoming chemotherapy resistance in metastatic cancer: a comprehensive review","volume":"12","author":"Eslami","year":"2024","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2025.01.014","article-title":"Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: a multicenter phase 2 PLATINUM trial","volume":"43","author":"Xu","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118743_bib7","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91737","article-title":"Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: a pilot study","volume":"12","author":"Chen","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.118743_bib8","series-title":"Advances in Cancer Treatment: from Systemic Chemotherapy to Targeted Therapy","author":"Cavalcanti","year":"2021"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118743_bib9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ijc.34027","article-title":"A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis","volume":"151","author":"Khalid","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118743_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","article-title":"The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art","volume":"84","author":"De Vos","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118743_bib11","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1021\/cr5004248","article-title":"New facets in the regulation of gene expression by ADP-ribosylation and poly (ADP-ribose) polymerases","volume":"115","author":"Ryu","year":"2015","journal-title":"Chem. Rev."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118743_bib12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/138161207780414241","article-title":"Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications","volume":"13","author":"de la Lastra","year":"2007","journal-title":"Curr. Pharm. Des."},{"issue":"Pt 10","key":"10.1016\/j.ejmech.2026.118743_bib13","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1107\/S1399004714017660","article-title":"Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2","volume":"70","author":"Qiu","year":"2014","journal-title":"Acta. Crystallogr. D Biol. Crystallogr."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118743_bib14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"Bioessays"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118743_bib15","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114002","article-title":"Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors","volume":"13","author":"Angers","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib16","first-page":"201","article-title":"Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited","volume":"1846","author":"Lupo","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1586\/era.10.53","article-title":"Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy","volume":"10","author":"Heitz","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.118743_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107924","article-title":"Synergy trap for guardian angels of DNA: unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition","volume":"153","author":"Elkafoury","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102078","article-title":"Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future","volume":"91","author":"Hu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118743_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.dnarep.2018.08.022","article-title":"The comings and goings of PARP-1 in response to DNA damage","volume":"71","author":"Pascal","year":"2018","journal-title":"DNA Repair"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118743_bib21","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tibs.2021.01.014","article-title":"Rapid detection and signaling of DNA damage by PARP-1","volume":"46","author":"Pandey","year":"2021","journal-title":"Trends Biochem. Sci."},{"issue":"7035","key":"10.1016\/j.ejmech.2026.118743_bib22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118743_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1537615","article-title":"PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy","volume":"16","author":"Matsumoto","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118743_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2024.103690","article-title":"The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication","volume":"140","author":"Zhang","year":"2024","journal-title":"DNA Repair"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105779","article-title":"Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging","volume":"26","author":"Mahadevan","year":"2023","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"issue":"13","key":"10.1016\/j.ejmech.2026.118743_bib27","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00018-012-0921-9","article-title":"Multiple roles of class I HDACs in proliferation, differentiation, and development","volume":"69","author":"Reichert","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118743_bib28","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/febs.13061","article-title":"Class II a HDAC s\u2013new insights into their functions in physiology and pathology","volume":"282","author":"Parra","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2026.118743_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-3-031-91459-1_9","article-title":"Acetylation in cardiac aging: molecular mechanism and therapeutic approaches","volume":"75","author":"Hase","year":"2025","journal-title":"Histone Non-Histone Revers. Acet. Dev. Aging Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118743_bib30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1142\/S2737416524500121","article-title":"Machine learning approaches to predict the selectivity of compounds against HDAC1 and HDAC6","volume":"23","author":"Dogan","year":"2024","journal-title":"J. Comput. Biophys. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117998","article-title":"Targeting histone deacetylase 1: inhibition and activation as promising therapeutic strategies for diverse disorders","author":"Costanzo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1568009622666220624090542","article-title":"Recent progress in histone deacetylase (HDAC) 1 inhibitors as anticancer agent","volume":"23","author":"Patel","year":"2023","journal-title":"Curr. Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-022-00704-6","article-title":"HDAC6: a unique HDAC family member as a cancer target","volume":"45","author":"Kaur","year":"2022","journal-title":"Cell. Oncol."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118743_bib34","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.2174\/0929867327666201111142653","article-title":"Recent development of novel HDAC6 isoform-selective inhibitors","volume":"28","author":"Zhao","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118743_bib35","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.2174\/0929867328666210902145102","article-title":"Dual targeting strategies on histone deacetylase 6 (HDAC6) and heat shock protein 90 (Hsp90)","volume":"29","author":"Bonanni","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib36","first-page":"1","article-title":"Epidrugs in cancer: mechanisms, applications, and future direction","author":"Bibi","year":"2025","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118743_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00425-024-04518-8","article-title":"Advances in understanding the roles of plant HAT and HDAC in non-histone protein acetylation and deacetylation","volume":"260","author":"Zhang","year":"2024","journal-title":"Planta"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cells11050863","article-title":"Insights into the histone acetylation-mediated regulation of the transcription factor genes that control the embryogenic transition in the somatic cells of arabidopsis","volume":"11","author":"Moro\u0144czyk","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118743_bib39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/pathophysiology29030038","article-title":"Critical functions of histone deacetylases (HDACs) in modulating inflammation associated with cardiovascular diseases","volume":"29","author":"Kulthinee","year":"2022","journal-title":"Pathophysiology"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/1570159X19666210609160017","article-title":"Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective","volume":"20","author":"Kumar","year":"2022","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118743_bib41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s12013-024-01587-0","article-title":"Histone deacetylases (HDACs) roles in inflammation-mediated diseases; current knowledge","volume":"83","author":"Jasim","year":"2025","journal-title":"Cell Biochem. Biophys."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118743_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor\u2013induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118743_bib43","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","article-title":"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","volume":"81","author":"Cong","year":"2021","journal-title":"Mol. Cell"},{"issue":"17","key":"10.1016\/j.ejmech.2026.118743_bib44","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/s41388-021-01744-2","article-title":"Exploiting synthetic lethality to target BRCA1\/2-deficient tumors: where we stand","volume":"40","author":"Patel","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118743_bib45","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/jm100012m","article-title":"Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic","volume":"53","author":"Ferraris","year":"2010","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/13543776.2021.1886275","article-title":"Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)","volume":"31","author":"Velagapudi","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118743_bib47","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3390\/cancers14112640","article-title":"Pharmacologic induction of BRCAness in BRCA-proficient cancers: expanding PARP inhibitor use","volume":"14","author":"Abbotts","year":"2022","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.ejmech.2026.118743_bib48","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.3390\/cancers15143642","article-title":"Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches","volume":"15","author":"Dilmac","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118743_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1552386","article-title":"PARP inhibitors in melanoma treatment: potential, challenges, and future directions","volume":"15","author":"Anaeme","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.118743_bib50","article-title":"Radiosynthesis and PET evaluation of [18F] fuzuloparib as a PARP-targeted imaging agent in breast cancer","author":"Xu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118743_bib51","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.31557\/APJCP.2025.26.6.1931","article-title":"Impact of olaparib, niraparib, rucaparib therapies on newly diagnosed and relapsed ovarian cancer-systematic review and meta-analysis","volume":"26","author":"Devi","year":"2025","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ejmech.2026.118743_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108761","article-title":"From bench to bedside: synthetic strategies and clinical application of PARP inhibitors","author":"Man","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118743_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.56782\/pps.185","article-title":"PARP inhibitors in ovarian cancer therapy","volume":"22","author":"Pisula","year":"2024","journal-title":"Prospect. Pharma. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118743_bib54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00280-024-04672-6","article-title":"Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers","volume":"94","author":"Du","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118743_bib55","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/iju.70100","article-title":"PARP inhibitors in genitourinary cancer: a new paradigm beyond prostate cancer","volume":"32","author":"Okuda","year":"2025","journal-title":"Int J Urol."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118743_bib56","doi-asserted-by":"crossref","first-page":"8494","DOI":"10.1080\/07391102.2021.1913229","article-title":"Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor","volume":"40","author":"Singh","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2026.118743_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114574","article-title":"Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone","volume":"240","author":"Kayumov","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118743_bib58","doi-asserted-by":"crossref","first-page":"16099","DOI":"10.1021\/acs.jmedchem.2c01352","article-title":"Multi-therapies based on PARP inhibition: potential therapeutic approaches for cancer treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/jmr.2891","article-title":"Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: molecular implications for ovarian cancer personalized therapy","volume":"34","author":"Zuo","year":"2021","journal-title":"J. Mol. Recogn."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118743_bib60","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1080\/17568919.2025.2561467","article-title":"Design, development, and therapeutic applications of PARP-1 selective inhibitors","volume":"17","author":"Xu","year":"2025","journal-title":"Future Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118743_bib61","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/nar\/gkh215","article-title":"Crystal structure of the catalytic fragment of murine poly (ADP\u2010ribose) polymerase\u20102","volume":"32","author":"Oliver","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib62","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/jm1010918","article-title":"5-Benzamidoisoquinolin-1-ones and 5-(\u03c9-carboxyalkyl) isoquinolin-1-ones as isoform-selective inhibitors of poly (ADP-ribose) polymerase 2 (PARP-2)","volume":"54","author":"Sunderland","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib63","series-title":"Design and Synthesis of Selective Inhibitors of Poly (ADP-ribose) polymerase-2","author":"Sunderland","year":"2010"},{"key":"10.1016\/j.ejmech.2026.118743_bib64","article-title":"Advances in structure-based PARP1 inhibitors: implications for cancer treatment","author":"Balachandran","year":"2025","journal-title":"Curr. Enzym. Inhib."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118743_bib134","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ccell.2021.06.018","article-title":"PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity","volume":"39","author":"Gozgit","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118743_bib137","series-title":"A first-in-human Phase 1 Study of a Novel PARP7 Inhibitor RBN-2397 in Patients with Advanced Solid Tumors","author":"Falchook","year":"2021"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib65","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/nar\/gkad066","article-title":"PARP1 associates with R-loops to promote their resolution and genome stability","volume":"51","author":"Laspata","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118743_bib66","series-title":"Unraveling the Interplay of XRN2 and PARP1 in Suppressing R-Loop-Generated Genomic Instability","author":"Viera","year":"2021"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118743_bib67","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41419-024-07277-2","article-title":"Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib68","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/s41598-020-59074-4","article-title":"The kinase polypharmacology landscape of clinical PARP inhibitors","volume":"10","author":"Antolin","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118743_bib69","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural basis for potency and promiscuity in Poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118743_bib138","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2174\/156802608784911581","article-title":"Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents","volume":"8","author":"Moradei","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"issue":"16_Supplement","key":"10.1016\/j.ejmech.2026.118743_bib135","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-DDT02-01","article-title":"Abstract DDT02-01: RBN-2397: a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways","volume":"80","author":"Vasbinder","year":"2020","journal-title":"Cancer Res."},{"issue":"1-2","key":"10.1016\/j.ejmech.2026.118743_bib70","first-page":"86","article-title":"BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality","volume":"39","author":"Khalizieva","year":"2025","journal-title":"Gene Dev."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib136","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s44321-025-00214-6","article-title":"PARP7 as a new target for activating anti-tumor immunity in cancer","volume":"17","author":"Popova","year":"2025","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118743_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127036","article-title":"Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1\/histone deacetylase-1 inhibitors","volume":"30","author":"Tian","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118743_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sbi.2019.01.004","article-title":"Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases","volume":"59","author":"Porter","year":"2019","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14366","article-title":"Discussion on structure classification and regulation function of histone deacetylase and their inhibitor","volume":"103","author":"Han","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-024-03771-w","article-title":"Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis","volume":"81","author":"Jin","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118743_bib74","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ijc.28940","article-title":"Personalised cancer medicine","volume":"137","author":"Jackson","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118743_bib75","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cclet.2019.06.019","article-title":"Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents","volume":"31","author":"Dai","year":"2020","journal-title":"Chin. Chem. Lett."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118743_bib76","doi-asserted-by":"crossref","first-page":"12643","DOI":"10.1080\/07391102.2023.2167122","article-title":"Cytosporone E analogues as BRD4 inhibitors for cancer treatment: molecular docking and molecular dynamic investigations","volume":"41","author":"Makki","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib77","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.apsb.2020.06.003","article-title":"Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy","volume":"11","author":"Chang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.118743_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113357","article-title":"Discovery of novel and potent PARP\/PI3K dual inhibitors for the treatment of cancer","volume":"217","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118743_bib79","doi-asserted-by":"crossref","first-page":"12707","DOI":"10.1021\/acsomega.8b02337","article-title":"Dual inhibitors of PARPs and ROCKs","volume":"3","author":"Antol\u00edn","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118743_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116739","article-title":"Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers","volume":"61","author":"Lin","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib81","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1038\/s41467-024-46593-1","article-title":"Discovery of a small-molecule inhibitor that traps Pol\u03b8 on DNA and synergizes with PARP inhibitors","volume":"15","author":"Fried","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib82","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/acs.jmedchem.3c02096","article-title":"Discovery and proof of concept of potent dual Pol\u03b8\/PARP inhibitors for efficient treatment of homologous recombination-deficient tumors","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib83","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1021\/acsomega.9b01106","article-title":"Small-molecule Poly(ADP-ribose) polymerase and PD-L1 inhibitor conjugates as dual-action anticancer agents","volume":"4","author":"Ofori","year":"2019","journal-title":"ACS Omega"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/biom11070981","article-title":"Dual PARP and RAD51 inhibitory drug conjugates show synergistic and selective effects on breast cancer cells","volume":"11","author":"Malka","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2026.118743_bib85","first-page":"1","article-title":"Emerging roles of PARP-1 driven dual inhibitors in cancer therapy: SAR-guided strategies and synthetic lethality","author":"Dhir","year":"2026","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107556","article-title":"Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1\/HDAC-1 inhibitors","volume":"151","author":"Wu","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118743_bib87","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1021\/acs.jmedchem.4c00090","article-title":"Design, synthesis, and structure-activity relationship of novel pyridazinone-based PARP7\/HDACs dual inhibitors for elucidating the relationship between antitumor immunity and HDACs inhibition","volume":"67","author":"Duan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103607","article-title":"Dual-target inhibitors of PARP1 in cancer therapy: a drug discovery perspective","volume":"28","author":"Zhang","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118743_bib89","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5582\/ddt.2021.01100","article-title":"Dual targeting, a new strategy for novel PARP inhibitor discovery","volume":"15","author":"Wei","year":"2021","journal-title":"Drug Discov. Ther."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118743_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158412","article-title":"PARP inhibitors: clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118743_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117185","article-title":"Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review","volume":"283","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118743_bib92","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1021\/acs.jmedchem.5c01677","article-title":"Advancements in hydrazide-based HDAC inhibitors: a review of recent developments and therapeutic potential","volume":"68","author":"Raucci","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib93","article-title":"Structural modifications and prospects of histone deacetylase (HDAC) inhibitors in cancer","author":"Chen","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.926577","article-title":"Histone acetylation dynamics in repair of DNA double-strand breaks","volume":"13","author":"Aricthota","year":"2022","journal-title":"Front. Genet."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118743_bib95","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib97","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118743_bib98","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118743_bib99","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2174\/0115734064320232240709105228","article-title":"Crucial structural understanding for selective HDAC8 inhibition: common pharmacophores, molecular docking, molecular dynamics, and zinc binder analysis of selective HDAC8 inhibitors","volume":"21","author":"Sarkar","year":"2025","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107556","article-title":"Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1\/HDAC-1 inhibitors","volume":"151","author":"Wu","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118743_bib101","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1021\/acs.jmedchem.4c00090","article-title":"Design, synthesis, and structure\u2013activity relationship of novel pyridazinone-based PARP7\/HDACs dual inhibitors for elucidating the relationship between antitumor immunity and HDACs inhibition","volume":"67","author":"Duan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib102","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118743_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.880643","article-title":"Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors","volume":"12","author":"Mekonnen","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118743_bib103","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.ejmech.2026.118743_bib104","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single inhibitors versus dual inhibitors: role of HDAC in cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118743_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112904","article-title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors","volume":"209","author":"Bass","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105166","article-title":"Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma","volume":"115","author":"Parag-Sharma","year":"2021","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejmech.2026.118743_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130362","article-title":"Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR\/HDAC3 dual-target inhibitors for the treatment of trithe ple-negative breast cancer","author":"Ge","year":"2025","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118743_bib108","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib109","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acsmedchemlett.0c00014","article-title":"Design of first-in-class dual EZH2\/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells","volume":"11","author":"Romanelli","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118743_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205018","article-title":"Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents","volume":"13","author":"Cincinelli","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118743_bib111","article-title":"Combined inhibition of PARP and EZH2 for cancer treatment: current status, opportunities, and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118743_bib112","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.bmc.2018.02.042","article-title":"Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors","volume":"26","author":"Yamashita","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118743_bib113","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1021\/acs.jmedchem.6b00157","article-title":"Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib114","first-page":"1083","article-title":"Design, synthesis, and biological evaluation of 2-Anilino-4-Triazolpyrimidine derivatives as CDK4\/HDACs inhibitors","author":"Wang","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118743_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127036","article-title":"Design, synthesis and anticancer activities of novel dual poly (ADP-ribose) polymerase-1\/histone deacetylase-1 inhibitors","volume":"30","author":"Tian","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118743_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128821","article-title":"Design, synthesis and antitumor activity study of PARP-1\/HDAC dual targeting inhibitors","volume":"71","author":"Chi","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib117","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118743_bib118","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-14-0173","article-title":"Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP","volume":"12","author":"Chao","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib119","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17568919.2024.2437975","article-title":"A short overview of dual targeting HDAC inhibitors","volume":"17","author":"Liu","year":"2025","journal-title":"Future Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118743_bib121","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","article-title":"Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib122","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biopha.2018.01.045","article-title":"Co-targeting poly (ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: higher synergism in BRCA mutated cells","volume":"99","author":"Marijon","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118743_bib123","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molonc.2015.12.014","article-title":"Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma","volume":"10","author":"Rasmussen","year":"2016","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib124","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118743_bib125","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.18632\/oncotarget.2154","article-title":"Histone deacetylase inhibitor treatment induces \u2018BRCAness\u2019 and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells","volume":"5","author":"Ha","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib127","article-title":"Synergy between HDAC and PARP inhibitors on proliferation of a human anaplastic thyroid cancer\u2010derived cell line","volume":"2015","author":"Baldan","year":"2015","journal-title":"Int. J. Endocrinol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118743_bib126","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2174\/1568026619666190603092407","article-title":"Recent study of dual HDAC\/PARP inhibitor for the treatment of tumor","volume":"19","author":"Lu","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118743_bib128","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.coph.2010.04.014","article-title":"Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs","volume":"10","author":"Teicher","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118743_bib129","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1016\/j.bmc.2017.05.058","article-title":"Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy","volume":"25","author":"Yuan","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112904","article-title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors","volume":"209","author":"Bass","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118743_bib131","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1016\/j.ejmech.2011.04.027","article-title":"Structure-based optimization of click-based histone deacetylase inhibitors","volume":"46","author":"Hou","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118743_bib132","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/jm5002502","article-title":"Discovery and structure\u2013activity relationship of novel 2, 3-Dihydrobenzofuran-7-carboxamide and 2, 3-Dihydrobenzofuran-3 (2 H)-one-7-carboxamide derivatives as poly (ADP-ribose) polymerase-1 inhibitors","volume":"57","author":"Patel","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118743_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128821","article-title":"Design, synthesis and antitumor activity study of PARP-1\/HDAC dual targeting inhibitors","volume":"71","author":"Chi","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118743_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701671","article-title":"Synergistic tumor cytolysis by NK cells in combination with a pan-HDAC inhibitor, panobinostat","volume":"12","author":"Afolabi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118743_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101779","article-title":"Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome na\u00efve resistance to pan-HDACi in diffuse large B cell lymphoma","volume":"39","author":"Havas","year":"2024","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118743_bib142","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/ph15040438","article-title":"Preclinical efficacy and toxicity analysis of the pan-histone deacetylase inhibitor gossypol for the therapy of colorectal cancer or hepatocellular carcinoma","volume":"15","author":"Mayer","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-023-01016-x","article-title":"Hematological toxicity of PARP inhibitors in metastatic prostate cancer patients with mutations of BRCA or HRR genes: a systematic review and safety meta-analysis","volume":"19","author":"Maiorano","year":"2024","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejmech.2026.118743_bib144","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejogrb.2024.12.021","article-title":"Haematological toxicity of PARP inhibitors in advanced ovarian cancer: a systematic review and meta-analysis","volume":"305","author":"Maiorano","year":"2025","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ejmech.2026.118743_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441222","article-title":"Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer","volume":"14","author":"Xie","year":"2024","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118743_bib146","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.3390\/ijms25179241","article-title":"Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: implications for novel therapeutic combinations","volume":"25","author":"Valdez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118743_bib147","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13046-022-02290-9","article-title":"Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/. BRCA1 DNA damage repair complex in prostate cancer cells","volume":"41","author":"Yin","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118743_bib148","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.3390\/cancers15102808","article-title":"Potential of synthetic and natural compounds as novel histone deacetylase inhibitors for the treatment of hematological malignancies","volume":"15","author":"Pal","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118743_bib149","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.18632\/oncotarget.28278","article-title":"HDAC inhibitors suppress protein poly (ADP-ribosyl) ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs","volume":"13","author":"Valdez","year":"2022","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.ejmech.2026.118743_bib151","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.2174\/0929867328666210915105929","article-title":"Histone deacetylases and their inhibitors in colorectal cancer therapy: current evidence and future considerations","volume":"29","author":"Garmpis","year":"2022","journal-title":"Curr. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:16:35Z","timestamp":1784668595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":150,"alternative-id":["S0223523426001881"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118743","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"InhibitWin duo: Rational design and structural insights into dual PARP\/HDAC inhibitors for synergistic DNA repair disruption and epigenetic modulation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118743"}}